X4 Pharmaceuticals, Inc. (XFOR)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about X4 Pharmaceuticals, Inc. (XFOR)
Go deeper and ask any question about XFOR
Company Performance
Current Price
as of Sep 13, 2024$0.71
P/E Ratio
8.29
Market Cap
$119.63M
Description
X4 Pharmaceuticals, Inc. is a late clinical-stage company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. Its clinical candidate is mavorixafor. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.
Metrics
Overview
- HQBoston, MA
- SectorHealth Technology
- IndustryBiotechnology
- TickerXFOR
- Price$0.71+4.72%
Trading Information
- Market Cap$119.63M
- Float69.91%
- Average Daily Volume (1m)755,366
- Average Daily Volume (3m)1,920,749
- EPS$0.09
Company
- Revenue$0.56M
- Rev Growth (1yr)N/A
- Net Income$90.83M
- Gross Margin17.94%
- EBITDA Margin-5,986.32%
- EBITDA-$33.70M
- EV$25.94M
- EV/Revenue46.07
- P/E8.29
- P/S253.23
Documents
SEC Filings